Analyst: This Stock Could Benefit From Middle East Tensions

SunTrust Robinson is bullish on FireEye's growth in 2020

by Patrick Martin

Published on Jan 7, 2020 at 9:48 AM

The shares of FireEye Inc (NASDAQ:FEYE) are up 2.5% to trade at $18 this morning, after SunTrust Robinson raised its rating to "buy" from "hold." The analyst in coverage -- while also upping its price target to $22 from $15 -- noted the Middle East tensions will lead to more government and private sector spending on cybersecurity. 

Should today's gains hold, FEYE is poised to start 2020 undefeated with four straight wins. Plus, that new price target sits in territory not achieved since late 2015. The $13 level contained the shares' bottom in August, and the subsequent rise has found support at their 50-day moving average. 

There's still pessimism surrounding FEYE that can be unwound should the cybersecurity name stay hot. There are 17 brokerages covering the stock and eight rate it a tepid "hold." Although short interest fell by 15.7% in the two most recent reporting periods, the 13.88 million shares sold short still accounts for a healthy 6.6% of the equity's total available float, and 4.1 times the average daily trading volume.

And in the options pits, near-term traders are put-heavy on FEYE, based on the Schaeffer's put/call open interest ratio (SOIR) of 0.99, which ranks in the 96th annual percentile, so a shift in sentiment among these speculators could also buffer FireEye's position on the charts.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Protect Your Retirement Savings Now
Click to continue to advertiser's site.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.